Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Price Target at $22.80

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has been given an average recommendation of “Moderate Buy” by the eight research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $22.80.

A number of brokerages have issued reports on ZVRA. Weiss Ratings restated a “sell (d+)” rating on shares of Zevra Therapeutics in a research note on Friday, January 9th. Cantor Fitzgerald reduced their price target on shares of Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. HC Wainwright set a $26.00 price objective on shares of Zevra Therapeutics in a report on Tuesday, December 30th. Canaccord Genuity Group dropped their target price on shares of Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research note on Thursday, November 6th. Finally, Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th.

Insider Buying and Selling at Zevra Therapeutics

In other news, CEO Neil F. Mcfarlane sold 91,000 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $9.38, for a total transaction of $853,580.00. Following the transaction, the chief executive officer owned 364,350 shares of the company’s stock, valued at $3,417,603. This represents a 19.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Joshua Schafer sold 3,375 shares of Zevra Therapeutics stock in a transaction dated Friday, January 30th. The stock was sold at an average price of $8.83, for a total value of $29,801.25. Following the completion of the sale, the insider directly owned 37,444 shares of the company’s stock, valued at approximately $330,630.52. This trade represents a 8.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 100,658 shares of company stock valued at $938,843. Company insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Zevra Therapeutics

Several institutional investors have recently added to or reduced their stakes in ZVRA. Ameritas Investment Partners Inc. increased its stake in shares of Zevra Therapeutics by 30.0% in the second quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock worth $49,000 after purchasing an additional 1,280 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Zevra Therapeutics by 9.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,294 shares of the company’s stock worth $179,000 after buying an additional 1,750 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Zevra Therapeutics by 6.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company’s stock valued at $238,000 after buying an additional 1,812 shares in the last quarter. CWM LLC grew its stake in Zevra Therapeutics by 399.5% in the 3rd quarter. CWM LLC now owns 2,872 shares of the company’s stock valued at $27,000 after buying an additional 2,297 shares in the last quarter. Finally, Carret Asset Management LLC raised its holdings in Zevra Therapeutics by 9.7% during the 2nd quarter. Carret Asset Management LLC now owns 39,640 shares of the company’s stock valued at $349,000 after acquiring an additional 3,500 shares during the period. 35.03% of the stock is owned by hedge funds and other institutional investors.

Zevra Therapeutics Trading Up 4.0%

NASDAQ:ZVRA opened at $9.36 on Friday. Zevra Therapeutics has a 52 week low of $6.19 and a 52 week high of $13.16. The firm has a 50-day moving average price of $8.66 and a two-hundred day moving average price of $9.43. The company has a debt-to-equity ratio of 0.46, a quick ratio of 8.57 and a current ratio of 8.62. The firm has a market cap of $526.95 million, a price-to-earnings ratio of 19.91 and a beta of 1.08.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Wednesday, November 5th. The company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. The firm had revenue of $26.06 million for the quarter, compared to the consensus estimate of $26.64 million. Zevra Therapeutics had a negative return on equity of 51.40% and a net margin of 41.93%. On average, equities analysts expect that Zevra Therapeutics will post -1.95 earnings per share for the current fiscal year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.